OpGen Inc (NASDAQ:OPGN) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $37.50 for the company and are anticipating that the company will post ($1.38) EPS for the current quarter, according to Zacks. Zacks has also given OpGen an industry rank of 107 out of 265 based on the ratings given to its competitors.
A number of equities analysts have issued reports on OPGN shares. Zacks Investment Research upgraded shares of OpGen from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research report on Tuesday, November 14th. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of OpGen in a research report on Wednesday, November 8th. Finally, ValuEngine cut shares of OpGen from a “sell” rating to a “strong sell” rating in a research report on Thursday.
OpGen (NASDAQ:OPGN) last announced its earnings results on Tuesday, November 7th. The medical research company reported ($1.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.00) by $0.25. OpGen had a negative net margin of 533.47% and a negative return on equity of 1,289.51%. research analysts predict that OpGen will post -10.25 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in OpGen stock. Perkins Capital Management Inc. purchased a new position in shares of OpGen Inc (NASDAQ:OPGN) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned approximately 2.72% of OpGen at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.83% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/27/zacks-opgen-inc-opgn-given-consensus-rating-of-strong-buy-by-brokerages.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.